Is doliracetam a classic racetam?

Not structurally. It is an indolin-2-one (oxindole) derivative from a 1982 Hoechst patent rather than a pyrrolidinone, so it is grouped with the racetams by convention and lineage rather than by the ring that defines the family.

Is there human evidence for doliracetam?

Essentially none. A PubMed search for doliracetam returns no dedicated studies, and no clinical or robust preclinical data are available. This entry is provided for reference only.

Its safety is unknown. There are no human safety data, no established dose and no validated protocol, so any use would be purely experimental. It is not an approved medicine.

EmergingResearch compoundReference only

Doliracetam

Name: Doliracetam
Creator: MolekulaX

Obscure experimental indolinone racetam from a 1982 Hoechst patent; virtually no human data.

NootropicRacetamRacetamMemoryAcetylcholineGlutamate

Pharmacology

ClassRacetam · Memory

Primary targetCholinergic transmission (proposed, weak modulation)

Targets3 receptor targets

Half-lifeN/A

OnsetN/A

EvidenceReference only

Affected systemsAcetylcholineGlutamate

Contents

WHAT IS DOLIRACETAM?

Detailed overview

Doliracetam (PubChem CID 208851, C16H14N2O2) is an obscure, experimental compound grouped with the racetams and first described in a 1982 Hoechst patent (EP 62887) covering indolinone-2 derivatives with claimed neuroanabolic properties. Chemically it is not a classic pyrrolidinone racetam but an indolin-2-one (oxindole) derivative, 2-(2-oxo-3-phenyl-2,3-dihydro-1H-indol-1-yl)acetamide. A well-defined mechanism of action has never been established in the published literature, and a PubMed search returns no dedicated clinical or preclinical studies. It is one of the most poorly documented racetams, so this entry is provided for reference only.

Mechanism

Uncharacterized (patent-claimed neuroanabolic)

Half-life

N/A

Onset

N/A

Legal status

Unapproved, unmarketed; reference material only

Receptor profile

Cholinergic transmissionWeak
AMPA glutamate receptorsWeak
Neuronal plasticityWeak

Safety

Side effects, stop signs, contraindications

Side effects · 3

With virtually no human data, the side-effect profile is unknown; racetam-like effects such as headache are plausible but unconfirmed
Theoretical choline-depletion headache, as with other racetams; a choline source may help in principle, but this is unproven
Unknown long-term safety: never marketed and with no clinical development on record

Contraindications · 3

Pregnancy and breastfeeding: no safety data, should be avoided
Not a medicine: human clinical trials have not established its safety, any use is experimental
Unknown drug interactions: the mechanism is uncharacterized, so co-administration risk cannot be estimated

Related Nootropics

Same therapeutic category

FAQ

Obscure experimental indolinone racetam from a 1982 Hoechst patent; virtually no human data.

Have a question about Doliracetam?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic

FormulaC16H14N2O2

UpdatedJuly 9, 2026

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA

Updated: July 9, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.